ATE305477T1 - Behandlung von insulinresistenz mit wachstumhormonfördernden stoffen - Google Patents

Behandlung von insulinresistenz mit wachstumhormonfördernden stoffen

Info

Publication number
ATE305477T1
ATE305477T1 AT98921683T AT98921683T ATE305477T1 AT E305477 T1 ATE305477 T1 AT E305477T1 AT 98921683 T AT98921683 T AT 98921683T AT 98921683 T AT98921683 T AT 98921683T AT E305477 T1 ATE305477 T1 AT E305477T1
Authority
AT
Austria
Prior art keywords
treatment
growth hormone
insulin resistance
promoting substances
hormone promoting
Prior art date
Application number
AT98921683T
Other languages
English (en)
Inventor
Philip Albert Carpino
Charles Kwok-Fung Chiu
Bruce Allen Lefker
Lydia Codetta Pan
Judith Lee Treadway
Michael Paul Zawistoski
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE305477T1 publication Critical patent/ATE305477T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
AT98921683T 1997-06-25 1998-06-05 Behandlung von insulinresistenz mit wachstumhormonfördernden stoffen ATE305477T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5079097P 1997-06-25 1997-06-25
PCT/IB1998/000876 WO1998058949A1 (en) 1997-06-25 1998-06-05 Treatment of insulin resistance with growth hormone secretagogues

Publications (1)

Publication Number Publication Date
ATE305477T1 true ATE305477T1 (de) 2005-10-15

Family

ID=21967444

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98921683T ATE305477T1 (de) 1997-06-25 1998-06-05 Behandlung von insulinresistenz mit wachstumhormonfördernden stoffen

Country Status (41)

Country Link
US (3) US6448263B1 (de)
EP (1) EP1000085B1 (de)
JP (2) JP2000514099A (de)
KR (1) KR20010014224A (de)
CN (2) CN1530107A (de)
AP (1) AP1145A (de)
AR (1) AR012256A1 (de)
AT (1) ATE305477T1 (de)
AU (1) AU747510B2 (de)
BG (1) BG104008A (de)
BR (1) BR9810477A (de)
CA (1) CA2294464A1 (de)
CO (1) CO4950621A1 (de)
DE (1) DE69831745T2 (de)
DZ (1) DZ2539A1 (de)
EA (1) EA002089B1 (de)
EG (1) EG21712A (de)
ES (1) ES2248899T3 (de)
HK (1) HK1028051A1 (de)
HN (1) HN1998000088A (de)
HR (1) HRP980361A2 (de)
HU (1) HUP0001922A3 (de)
ID (1) ID24345A (de)
IL (7) IL154114A0 (de)
IN (1) IN189724B (de)
IS (1) IS5275A (de)
MA (1) MA24581A1 (de)
NO (1) NO996205D0 (de)
NZ (1) NZ500655A (de)
OA (1) OA11242A (de)
PA (1) PA8452601A1 (de)
PE (1) PE105399A1 (de)
PL (1) PL337659A1 (de)
SK (1) SK175699A3 (de)
TN (1) TNSN98113A1 (de)
TR (1) TR199903257T2 (de)
TW (1) TW553943B (de)
UA (1) UA64751C2 (de)
WO (1) WO1998058949A1 (de)
YU (1) YU70199A (de)
ZA (1) ZA985546B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
US6541634B2 (en) 1999-02-26 2003-04-01 Pfizer Inc. Process for preparing growth hormone secretagogues
US7721948B1 (en) * 1999-05-25 2010-05-25 Silverbrook Research Pty Ltd Method and system for online payments
EP1132388A3 (de) * 2000-03-09 2004-03-03 Pfizer Products Inc. Metaboliten von Hexahydropyrazolo[4,3-c]pyridinen
ES2333097T3 (es) 2000-05-31 2010-02-17 Raqualia Pharma Inc Uso de secretagogos de la hormona de crecimiento para estimular la motilidad gastrointestinal.
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
KR20050071498A (ko) * 2002-09-18 2005-07-07 상트르 오스피딸리에 드 루니버시떼 드 몬트리알 성장 호르몬 방출 호르몬 유사체
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
JP2008524427A (ja) * 2004-12-21 2008-07-10 ハーキュリーズ・インコーポレーテッド 亜硫酸イオンを含む製紙系において乾燥および湿潤紙力増強剤として使用するための反応性を有するカチオン性樹脂
US20070024388A1 (en) * 2005-07-27 2007-02-01 Hassan Tanbakuchi Slabline structure with rotationally offset ground
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
KR20090107088A (ko) 2007-02-09 2009-10-12 트랜자임 파르마 인크 거대고리 그렐린 수용체 조절제 및 이의 사용 방법
US7862825B2 (en) * 2007-02-21 2011-01-04 Mladen Vranic Method of controlling tight blood glucose by somatostatin receptor antagonists
UY34094A (es) 2011-05-27 2013-01-03 Novartis Ag Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
AU2013255458A1 (en) 2012-05-03 2014-10-09 Novartis Ag L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists
MX360906B (es) * 2013-05-28 2018-11-21 Raqualia Pharma Inc Forma cristalina del l-tartrato de 2-amino-n[2-(3a-(r)- bencil-2-metil-3-oxo-2,3,3a,4,6,7-hexahidro-pirazolo[4,3-c]piridi n-5-il)-1-(r)-benciloximetil-2-oxo-etil]-isobutiramida.
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
MX2017001408A (es) * 2014-08-05 2017-05-10 Raqualia Pharma Inc Derivados de serina como agonistas del receptor de grelina.
CN106795158A (zh) * 2014-10-31 2017-05-31 拉夸里亚创药株式会社 作为生长激素释放肽受体激动剂的四氢吡唑并吡啶衍生物
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3235550A (en) 1966-02-15 Anal g gesiaxoat t tail intravenous injection
US3202660A (en) 1961-10-09 1965-08-24 Boehringer Sohn Ingelheim Process for the preparation of 3-arylamino-1, 3-diazacycloalkenes
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
GB2101114B (en) 1981-07-10 1985-05-22 Farmos Group Ltd Substituted imidazole derivatives and their preparation and use
US5242783A (en) 1991-07-31 1993-09-07 Eastman Kodak Company Photographic material and process
JPH08503213A (ja) 1992-11-06 1996-04-09 メルク エンド カンパニー インコーポレーテッド 成長ホルモンの放出を促進する置換ジペプチド同族体
PL176993B1 (pl) 1992-12-11 1999-08-31 Merck & Co Inc Nowe związki spiropiperydynowe oraz sposób ich wytwarzania
EP0739204A4 (de) 1993-11-09 2000-03-15 Merck & Co Inc Piperidine, pyrrolidine und hexahydro-1h-azepine unterstützen die freisetzung des wachstumshormon
US5492916A (en) * 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
BR9610277A (pt) 1995-08-31 1999-07-06 Schering Corp Derivados de piperazino como antagonistas de neurowuinina
EP0766966A3 (de) * 1995-09-08 2001-02-28 Eli Lilly And Company Methode zur Behandlung der Insulinresistenz
CN1211991A (zh) 1995-12-22 1999-03-24 诺沃挪第克公司 具有生长激素释放性质的化合物
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
JP3514774B2 (ja) * 1997-06-25 2004-03-31 ファイザー・インク 成長ホルモン分泌促進薬としてのジペプチド誘導体
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)

Also Published As

Publication number Publication date
PE105399A1 (es) 1999-11-04
UA64751C2 (uk) 2004-03-15
OA11242A (en) 2003-07-23
PA8452601A1 (es) 2000-05-24
ID24345A (id) 2000-07-13
EP1000085A1 (de) 2000-05-17
DZ2539A1 (fr) 2003-02-08
AR012256A1 (es) 2000-09-27
HN1998000088A (es) 1999-01-08
HUP0001922A3 (en) 2001-02-28
HK1028051A1 (en) 2001-02-02
IL154116A0 (en) 2003-07-31
CN1259140A (zh) 2000-07-05
AU747510B2 (en) 2002-05-16
DE69831745T2 (de) 2006-08-31
YU70199A (sh) 2003-01-31
DE69831745D1 (de) 2006-02-09
IL133626A0 (en) 2001-04-30
CO4950621A1 (es) 2000-09-01
AP9801267A0 (en) 1998-06-30
NO996205L (no) 1999-12-15
IN189724B (de) 2003-04-19
US6867202B1 (en) 2005-03-15
US6630487B2 (en) 2003-10-07
PL337659A1 (en) 2000-08-28
IL154115A0 (en) 2003-07-31
EA002089B1 (ru) 2001-12-24
MA24581A1 (fr) 1998-12-31
AU7445698A (en) 1999-01-04
TR199903257T2 (xx) 2000-12-21
SK175699A3 (en) 2001-04-09
BR9810477A (pt) 2007-05-22
US20030100561A1 (en) 2003-05-29
NO996205D0 (no) 1999-12-15
HRP980361A2 (en) 1999-02-28
ZA985546B (en) 2000-01-10
WO1998058949A1 (en) 1998-12-30
US6448263B1 (en) 2002-09-10
EG21712A (en) 2002-02-27
CN1152049C (zh) 2004-06-02
ES2248899T3 (es) 2006-03-16
JP2000514099A (ja) 2000-10-24
HUP0001922A2 (hu) 2000-12-28
IL154112A0 (en) 2003-07-31
IL156465A0 (en) 2004-01-04
CN1530107A (zh) 2004-09-22
KR20010014224A (ko) 2001-02-26
BG104008A (en) 2000-07-31
AP1145A (en) 2003-02-14
IL154114A0 (en) 2003-07-31
EA199901075A1 (ru) 2000-08-28
EP1000085B1 (de) 2005-09-28
TW553943B (en) 2003-09-21
JP3742643B2 (ja) 2006-02-08
JP2005097261A (ja) 2005-04-14
TNSN98113A1 (fr) 2005-03-15
IS5275A (is) 1999-11-26
IL156465A (en) 2004-07-25
IL154111A0 (en) 2003-07-31
NZ500655A (en) 2002-02-01
CA2294464A1 (en) 1998-12-30

Similar Documents

Publication Publication Date Title
DE69831745D1 (de) Behandlung von insulinresistenz mit wachstumhormonfördernden stoffen
DE60030109D1 (de) (-)(3-trihalomethylphenoxy) (4-halophenyl) zur behandlung von insulinresistenz und typ ii diabetes
DE69720243D1 (de) Chemische modifikation von biomedizinischen materialien mit genipin
DE69836640D1 (de) Vorrichtung zur behandlung von gewebe mit mehrfach-elektroden
DE69817446D1 (de) Behandlung von diabetes
DE69710095T2 (de) Pharmazeutische zubereitung zur behandlung von diabetes
ATE256463T1 (de) Pharmazeutische zubereitung zur verwendung in der behandlung von diabetes
DE69731736D1 (de) Injektionsbehandlung zur beherrschung von muskelkrämpfen und damit einhergehenden schmerzen
DE69830591D1 (de) HEILUNG VON BRUCHVERLETZUNGEN UNTER VERWENDUNG VON PTHrP ANALOGEN
DE69838338D1 (de) Verwendung von antimykotica zur topischen behandlung von pilz-induzierten schleimhautentzündungen
ATE355840T1 (de) Behandlung der diabetes mit thiazolidindione und metformin
DE69821520D1 (de) Verwendung von alkylierten iminozuckern zur behandlung von multipler medikamentenresistenz
DE69325772D1 (de) Implantierbarer Herzschrittmacher mit anpassbarem AV-Intervall zur Behandlung von Kardiomyopathie
DE69826045D1 (de) Multi-Ort Herzschrittmacher zur Behandlung von Herzinsuffizienzen mit Reizimpulsen
DE69829763D1 (de) Verwendung von tetrahydolipstatin in der behandlung von diabetes typ ii
ATE305790T1 (de) Behandlung der diabetes mit thiazolidindione, insulin sekretionförderer und biguanide
NO975718L (no) Behandling av insulinresistens
DE69837148D1 (de) Chimäre proteine zur behandlung von diabetes
DE69619051D1 (de) Behandlung von Füllstoffen mit Oxasilacycloalkanen
DE69834937D1 (de) Antibiotika zur behandlung von magengeschwuren
DE990441T1 (de) Arzneimittel zur behandlung von diabetischer nephrosis
DE69837089D1 (de) Behandlung der diabetes mit thiazolidindione und sulphonylurea
DE69838066D1 (de) Behandlung der diabetes mit thiazolidindione und sulphonylurea
DE69017825D1 (de) Heilverfahren von Lebererkrankungen mit Verwendung von Pyrrol-Chinolin-Chinone-Triester und neue Pyrrol-Chinolin-Chinone-Triester.
DE59813114D1 (de) BK-RiV-Präparate zur Behandlung von proliferativen Zellerkrangungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties